Yasser Riazalhosseini

Home / Investigators  / Yasser Riazalhosseini

Yasser Riazalhosseini

Assistant Professor, Department of Human Genetics

Phone: (514) 398-1784

740 Dr Penfield Ave, Room 4203
Montréal, Québec, Canada, H3A 0G1


While collaborating on genome characterization of different tumor entities, research in the lab is focused on following topics:

Comprehensive molecular understanding of renal cell carcinoma
Renal cell carcinoma (RCC) is the most common form of kidney tumors. RCC has different subtypes with clear cell (ccRCC; conventional) being the most frequently diagnosed subtype accounting for 75-80% of RCCs. The incidence of RCC is increasing worldwide, but there is no biological marker for routine clinical use. Furthermore, it is essential to identify novel therapies as RCCs are resistant to conventional chemo- and radio-therapy.

We have recently generated comprehensive genome, epigenome and transcriptome landscapes of ccRCC. In an integrative manner, our lab is dissecting these profiles in order to identify molecular aberrations that possess cancer-driving activities. We have also extended our research to characterize molecular aberrations of other subtypes of RCC including papillary and chromophobe tumors, whose genetic abnormalities are less understood.

Post-transcriptional regulatory programs in cancer
In parallel to analyzing (epi)genome patterns, as factors governing gene expression at transcriptional level, we are investigating role of non-coding transcripts including long non-coding RNAs and microRNAs (miRNAs) as well as RNA binding proteins (RBPs) in post-transcriptional deregulation of cancer transcriptome. Specifically, we combine cancer-associated gene expression patterns with regulatory networks of miRNAs and RBPs, and apply quantitative approaches to these profiles in order to predict factors whose aberrant function can explain the abnormal transcriptome of tumor samples. These potentially “master regulators” are then subjected to experimental verification for their driver activities.

Investigating intra-tumoral heterogeneity and its contribution to metastasis
Approaches to stratifying risk or tailoring therapy for individual cancer patients based on the molecular profile of their tumor biopsy are complicated by the existence of genetic heterogeneity (representing distinct populations of cancer cells with different sets of mutations; subclones) both within and across tumors. Furthermore, across tumor sites, genomes of disseminated cancer cells may have similarities at the onset of metastatic disease, but substantial changes in the genetic composition occur spatially and over time, supporting the suggestion that the expansion of aggressive driver clone(s) and the emergence of relevant subclones correlate with development of incurable disease and potential therapeutic resistance. Our lab has optimized protocols of NGS on minutes amount of DNA as well as on DNA isolated from Formalin-fixed, paraffin-embedded (FFPE) samples providing an opportunity to analyze archived primary tumors of patients affected with metastatic or recurrent disease. We analyze the heterogeneous clonal composition of primary and metastatic tumors in order to investigate genomic evolution of metastasis.

Recent Publications

  • Glennon, KI, Maralani, M, Abdian, N, Paccard, A, Montermini, L, Nam, AJ et al.. Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma. Cancers (Basel). 2021;13 (22):. doi: 10.3390/cancers13225825. PubMed PMID:34830979 PubMed Central PMC8616270.
  • Bergholtz, H, Carter, JM, Cesano, A, Cheang, MCU, Church, SE, Divakar, P et al.. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler. Cancers (Basel). 2021;13 (17):. doi: 10.3390/cancers13174456. PubMed PMID:34503266 PubMed Central PMC8431590.
  • Willis-Owen, SAG, Domingo-Sabugo, C, Starren, E, Liang, L, Freidin, MB, Arseneault, M et al.. Y disruption, autosomal hypomethylation and poor male lung cancer survival. Sci Rep. 2021;11 (1):12453. doi: 10.1038/s41598-021-91907-8. PubMed PMID:34127738 PubMed Central PMC8203787.
  • Khalesi, R, Razmara, E, Asgaritarghi, G, Tavasoli, AR, Riazalhosseini, Y, Auld, D et al.. Novel manifestations of Warburg micro syndrome type 1 caused by a new splicing variant of RAB3GAP1: a case report. BMC Neurol. 2021;21 (1):180. doi: 10.1186/s12883-021-02204-w. PubMed PMID:33910511 PubMed Central PMC8080372.
  • Tawil, N, Bassawon, R, Meehan, B, Nehme, A, Montermini, L, Gayden, T et al.. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv. 2021;5 (6):1682-1694. doi: 10.1182/bloodadvances.2020002998. PubMed PMID:33720339 PubMed Central PMC7993100.
  • Abedi-Ardekani, B, Nasrollahzadeh, D, Egevad, L, Banks, RE, Vasudev, N, Holcatova, I et al.. Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer. Virchows Arch. 2021;478 (6):1099-1107. doi: 10.1007/s00428-020-02986-3. PubMed PMID:33403511 PubMed Central PMC8203524.
  • Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):6232. doi: 10.1038/s41467-020-20128-w. PubMed PMID:33257764 PubMed Central PMC7705717.
  • Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):4748. doi: 10.1038/s41467-020-18151-y. PubMed PMID:32958763 PubMed Central PMC7505971.
  • Li, CH, Prokopec, SD, Sun, RX, Yousif, F, Schmitz, N, PCAWG Tumour Subtypes and Clinical Translation et al.. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11 (1):4330. doi: 10.1038/s41467-020-17359-2. PubMed PMID:32859912 PubMed Central PMC7455744.
  • Wang, Y, Park, JYP, Pacis, A, Denroche, RE, Jang, GH, Zhang, A et al.. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Clin Cancer Res. 2020;26 (20):5462-5476. doi: 10.1158/1078-0432.CCR-20-1439. PubMed PMID:32816949 .
Search PubMed